Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

22.91
-0.7400-3.13%
Post-market: 22.80-0.1100-0.48%19:58 EDT
Volume:917.88K
Turnover:21.20M
Market Cap:396.37M
PE:-2.41
High:24.32
Open:24.19
Low:22.59
Close:23.65
Loading ...

Nektar Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
25 Jun

Crude Oil Falls Sharply; US Current Account Deficit Widens In Q1

Benzinga
·
25 Jun

Wainwright sets over $100 target for Nektar on ‘paradigm-shifting’ data

TIPRANKS
·
25 Jun

BUZZ-U.S. STOCKS ON THE MOVE-US airlines, Snowflake, Supermicro

Reuters
·
24 Jun

Sector Update: Health Care Stocks Edge Higher Premarket Tuesday

MT Newswires Live
·
24 Jun

Nektar jumps 130% to $21.90 after atopic dermatitis study success

TIPRANKS
·
24 Jun

BRIEF-Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis

Reuters
·
24 Jun

Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial

Reuters
·
24 Jun

Stocks to Watch: Nektar Therapeutics, Alset

Dow Jones
·
24 Jun

Nektar to announce induction period in REZOLVE-AD study of Rezpegaldesleukin

TIPRANKS
·
24 Jun

Nektar Therapeutics to Unveil Top-Line Data from Phase 2b Study of Rezpegaldesleukin for Atopic Dermatitis on June 24, 2025

Reuters
·
24 Jun

Nektar trading halted, news pending

TIPRANKS
·
07 Jun

BRIEF-Nektar Therapeutics Increases Authorized Shares To 390 Million

Reuters
·
07 Jun

Nektar Therapeutics Amends Bylaws, Increases Authorized Shares and Announces Reverse Stock Split

Reuters
·
07 Jun

Nektar Therapeutics Announces 1-for-15 Reverse Stock Split Effective June 8, 2025

Reuters
·
05 Jun

Nektar Therapeutics Elects New Board, Approves Key Proposals

TIPRANKS
·
28 May

Nektar Therapeutics Conducted Annual Stockholders Meeting

Reuters
·
28 May

Nektar Therapeutics' Chief Legal Officer Mark A. Wilson Reports Disposal of Common Shares

Reuters
·
22 May

Nektar Therapeutics CEO Howard W. Robin Reports Disposal of Common Shares

Reuters
·
22 May

Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)

TIPRANKS
·
19 May